Zure produktuak, zerbitzuak edo biak beste enpresa batengandik bereizi nahi badituzu, baliteke marka edo izen komertzial bat behar izatea. Ezagutu zer diren, zer den erregistratzeko prozedura eta zer dakarren.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Arazo tekniko bat konpontzen duen edo abantaila praktiko bat duen gailu, produktu edo prozedura berri bat baduzu, hura babesteko hainbat modu daude Espainian eta beste herrialde batzuetan. Ikusi nola egin.
Zure berrikuntza zure produktuaren estetikan, apainduran edo itxuran datza? Babestu diseinu industrial baten bidez. Jakin ezazu zer eskubide ematen dituen erregistroak eta nola egin izapideak.
Mundu osoan argitaratutako patenteak informazio zientifiko, tekniko eta komertzialaren iturri baliotsua dira.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
Ekintzailea edo enpresa bazara eta zure negozioaren errentagarritasuna sustatu eta hobetu nahi baduzu, zure erakundeko aktibo ukiezinak behar bezala babestuz, gune honetan aurkituko duzu behar duzuna.
216
resultados
Última actualización
09/10/2025 [12:44:00]
Resultados 75 a 100 de 216
Resumen de: WO2025200113A1
Provided is a superoxide dismutase-based nanoscale transdermal delivery system, which is a capsule composite structure consisting of a small molecule active ingredient, superoxide dismutase, and a polymer coating. The small molecule active ingredient is loaded in the superoxide dismutase, and the surface of the superoxide dismutase is coated with the polymer coating. The superoxide dismutase-based active ingredient transdermal delivery system has a diameter of 20-100 nm, and the polymer coating has a thickness of 7.5-52.5 nm. In the delivery system, the polymer coating protects the superoxide dismutase and the small molecule functional substance having an antioxidant effect, and the capsule composite structure is in the form of nanogel. The nanogel not only promotes the penetration depth of the delivery system, but also mitigates the stimulation of the delivery system to the skin. The delivery system features biofriendly starting materials, simple preparation method, and high yield, and thus can be produced in large scale industrially.
Resumen de: WO2025207519A1
Embodiments of the present disclosure pertain to an active agent carrier that includes a disc-shaped membrane with a plurality of self-assembled amphiphilic block copolymers encased by membrane stabilizing agents, where the amphiphilic block copolymers include hydrophilic blocks and hydrophobic blocks, and where at least one active agent is associated with the disc-shaped membrane. Tunable numbers of targeting agents may also be associated with the disc-shaped membrane. Additional embodiments pertain to methods of delivering one or more active agents to a subject by administering to the subject an active agent carrier of the present disclosure. Further embodiments pertain to methods of making an active agent carrier of the present disclosure.
Resumen de: WO2025200270A1
A cationic lipid compound, a preparation method therefor, a composition comprising same, and a use thereof, relating to the technical field of biomedicine. The cationic lipid compound has relatively high transfection efficiency and relatively low cytotoxicity by introducing at least one protonatable polar headgroup containing a secondary or tertiary amine and at least two hydrophobic tails containing a specified number of carbons, and connecting the polar headgroup and the hydrophobic tails by means of a specific linker chain.
Resumen de: WO2025207378A1
Surface modification of nanoparticles (NPs) via the layer-by-layer (LbL) technique is a approach to generate targeted drug delivery vehicles. A simple and scalable synthesis method for LbL-NPs that can be adapted for clinical translation is of great interest. Presented herein is a robust and scalable method of polymer deposition onto nanoparticles.
Resumen de: WO2025207828A1
This disclosure is directed to payload bioactive agents (PBAs) that include modified exatecans. This disclosure is also directed to bioactive compositions and pharmaceutical compositions for treating cancer. The pharmaceutical compositions comprise a polymer, a targeting bioactive agent (TBA), a PBA comprising a modified exatecan that is covalently linked to the TBA directly or indirectly, a linker that can comprise a cleavable linker, and a pharmaceutical suitable carrier. The pharmaceutical compositions can be antibody-drug conjugates (ADCs) for treating cancers, with the potential for treating tumors having negative or low (AgLow) tumor antigens.
Resumen de: WO2025206286A1
The present invention addresses the problem of providing a composition for freeze-drying cells with which it is possible to suppress a decrease in survival rate or a decrease in particle size when the cells are reconstituted after freeze-drying. The composition for freeze-drying cells contains (a) a hydrophobic substance such as (a-1), (a-2), etc., and (b) nanoparticles formed from monolayers or bilayers of amphiphilic molecules, where: (a-1) is one or more hydrophobic amino acids selected from the group consisting of phenylalanine, leucine, glycine, valine, isoleucine, tryptophan, and alanine; and (a-2) is a dipeptide configured from one or two hydrophobic amino acids selected from the group consisting of phenylalanine, leucine, glycine, valine, isoleucine, tryptophan, and alanine. The composition is characterized by being used added to the cells.
Resumen de: WO2025200185A1
An astragaloside nanoformulation for the treatment of hepatitis B and a preparation method therefor. The astragaloside nanoformulation for the treatment of hepatitis B comprises astragaloside and an auxiliary material. The auxiliary material comprises at least one of a polyoxyethylene-polyoxypropylene ether triblock copolymer, phospholipid, albumin, and casein. The compounding of these auxiliary materials and astragaloside can result in an astragaloside nanoformulation with good water solubility and high bioavailability, which exhibits higher safety and efficacy for the treatment of hepatitis B.
Resumen de: WO2025207807A1
The disclosure provides a nanoparticle comprising a positively-charged surface and an interior comprising (i) a core and (ii) at least two nucleic acid layers, wherein each nucleic acid layer is positioned between a cationic lipid bilayer, and nucleic acid molecules in the nucleic acid layers comprise a sequence of a nucleic acid molecule expressed by a circulating tumor cell (CTC). The disclosure further provides a method of treating cancer in a subject need thereof, the method comprising administering to the subject the nanoparticle described herein, optionally wherein two or more administrations of the nanoparticle are provided, wherein each administration comprises a nanoparticle comprising RNA comprising a sequence of RNA expressed in a CTC isolated from the subject at different points in time.
Resumen de: CN120359038A
The present disclosure provides inhibitory nucleic acids, compositions comprising the inhibitory nucleic acids, and methods of using the inhibitory nucleic acids to treat various diseases.
Resumen de: AU2023385865A1
Disclosed herein are dense nanolipid fluid (DNLF) dispersions comprising desirable characteristics for incorporating bioactive agents such as peptides into lipid phase of the dispersion for biodelivery of the agents for their typical purpose. Continuous methods for preparing the DNLF dispersions are also disclosed herein to include formation of a crude mill base and passing the base through a twin screw extruder. Dispersions disclosed herein can express a particle size of less than 150 nm under stable storage conditions, while forming lamellar structures after exposure to heat and/or evaporation of the aqueous components of the dispersion.
Resumen de: EP4624460A1
Provided in the present invention are an ionizable lipid, and a drug delivery system containing the ionizable lipid. Specifically, provided in the present invention is an ionizable lipid having the structure of formula (I), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. A lipid nanoparticle constructed by means of using the ionizable lipid can realize safe and efficient delivery of nucleic acid drugs, small-molecule drugs, peptide drugs and protein drugs.
Resumen de: EP4624451A1
The present invention belongs to the field of biomedicine, which discloses a class of lipid compounds containing carbamate bond and applications thereof. The lipid compounds have the following structures:wherein the definitions of the various groups are described in the specification. The lipid nanoparticulate carriers prepared from the compounds described in the present invention exhibit excellent biocompatibility and safety as well as unexpected improvements in transfection efficiency, making them suitable for biomedical industrialization.
Resumen de: WO2024108303A1
Lymphoid leukemia such as acute lymphoblastic leukemia (ALL) represents a devastating disease especially when it occurs in adults. While dose-intensification strategies have led to a significant improvement in outcomes for pediatric patients, prognosis for the elderly remains very poor, with only 30-40% of adult patients with ALL achieving long-term remission. Novel tumor-specific antigens (TSAs) shared by a large proportion of lymphoid leukemia cells are described herein. Most of the TSAs described herein derives from aberrantly expressed unmutated genomic sequences, such as intronic and intergenic sequences, which are not expressed in normal tissues. Nucleic acids, compositions, cells and vaccines derived from these TSAs are described. The use of the TSAs, nucleic acids, compositions, cells and vaccines for the treatment of leukemia such as lymphoid leukemia is also described.
Resumen de: WO2024102746A1
Methods are described for treating neurotrophic keratitis in a subject by administering an agent that inhibits fidgetin-like 2 activity, such as by using an RNA interference agent, e.g., siRNA.
Resumen de: GB2639579A
An antimicrobial composition comprising an antimicrobial compound and a population of metal nanoparticles is provided. The antimicrobial compound is preferably an antibiotic. The metal nanoparticle may comprise silver and/or copper and may also comprise a polymer coating such as poly(N-vinylpyrrolidone). The antimicrobial composition wherein the population of silver nanoparticles is formed by (a) mixing a first aqueous alkaline solution with an aqueous polymer solution to form an aqueous polymer solution; and (b) mixing the aqueous alkaline polymer solution with an aqueous solution of a metal salt to form a solution of polymer-coated metal nanoparticles is provided. A coating or treatment for a surface or substrate comprising the antimicrobial composition is provided. A medical device comprising the coating or treatment is provided. The medical device may be a wound care dressing or a bandage. A silver nanoparticle coated with poly(N-vinylpyrrolidone) is exemplified. Combinations of the PVP-coated silver nanoparticles (AgNP) and various antibiotics were tested. Compositions comprising silver nanoparticles and aminoglycosides, such as kanamycin and gentamicin, were particularly effective. A combination of silver nanoparticles and ebselen was also particularly effective against E. coli and S. aureus.
Resumen de: CN120265279A
The present disclosure provides stable dry powder messenger RNA formulations for therapeutic use and methods of making and using the same.
Resumen de: WO2024112867A1
Nanoparticles having a calcium core, such as calcium hydroxide (Ca(OH)2) and calcium carbonate (CaCO3) particles are provided. The nanoparticles can further include a shell such as one formed of silica or oleic acid. The nanoparticles can further include a coating, such as one formed of polyethylene glycol and optionally further including a lipid. The nanoparticles can further include a targeting agent, such as one that targets dendritic cells, T cells, or other immune cells. The nanoparticles can further include or otherwise be used in combination with an active agent, optionally selected from an antigen, chemotherapeutic drug, immune system modulator, or immune checkpoint modulator. Pharmaceutical compositions including the nanoparticles and methods of use thereof for increasing immune response, e.g., against cancer and infections are also provided.
Resumen de: WO2024110757A1
The invention provides constructs, pharmaceutical compositions, methods of preparing a ferritin nanocage, ferritin nanocages, methods of treating or preventing a disease in a subject, and methods of raising an immune response against an antigen. Exemplary constructs include two ferritin subunits connected by a linker, wherein the linker includes a cleavage site, wherein the linker is arranged to prevent the ferritin subunits from self-assembling into a ferritin nanocage, and wherein cleavage of the linker at the cleavage site does not prevent the ferritin subunits from self-assembling into a ferritin nanocage.
Resumen de: US2025268840A1
There are disclosed methods of treating a subject or an object in need thereof, the method comprising administering compositions comprising nano-elements containing: a) at least one water-insoluble thermoplastic compound (WITC), capable of forming a core; and b) at least one active agent which can be disposed in said core or in shells surrounding the core. The nano-elements, having an average diameter in the sub-micron range, are constituted of materials having a low vapor pressure and are dispersible in a polar carrier. Methods for preparing these nano-elements, and administering them, so as to treat conditions corresponding to the active agents contained therein, are also provided.
Resumen de: WO2024110492A1
The invention relates to a carrier comprising at least one polar cationizable domain (PCD), two or more apolar cationizable domains (ACD) and at least one branching connector (BC), wherein the two or more ACDs are linked by at least one branching connector to at least one PCD, wherein the PCD is an oligo(alkylamino) acid, an ε-poly-L-lysine or an ε-poly-L-lysine-6-Ahx, and the ACD is a lipo amino fatty acid (LAF) comprising a tertiary amine. The invention further relates to nanoparticles comprising said carrier and a cargo, wherein the cargo comprises a nucleic acid and/or a protein and to a pharmaceutical composition comprising said nanoparticles and to its use in therapy or in in vitro culture.
Resumen de: CN120225501A
The present invention provides an ionizable lipid of formula (I) or a pharmaceutically acceptable salt thereof or a stereoisomer of any of them; a lipid nanoparticle comprising the ionizable lipid (in particular as an encapsulant), optionally comprising a pharmaceutically active agent; and a pharmaceutical composition comprising the lipid nanoparticles. The present invention also provides a lipid nanoparticle for a drug or a pharmaceutical composition comprising the same, and a use of the lipid nanoparticle as an encapsulant. # imgabs0 #
Resumen de: MX2025011000A
The present disclosure provides a method of treating or ameliorating an operative complication of a cataract surgery. The method comprises administering nanoparticles of clobetasol propionate to a subject in need thereof.
Resumen de: MX2025010536A
The present invention provides novel ionizable lipids and novel lipid nanoparticles comprising messenger RNA (mRNA) useful for the delivery of nucleic acids, related pharmaceutical compositions or vaccines as defined herein for use in human or veterinary medicine, in particular for use in the treatment and/or prophylaxis of cancer diseases.
Resumen de: EP4624462A2
The present disclosure provides a C6'-substituted locked nucleic acid-modified cap analog and a use thereof, wherein the cap analog improves the stability of mRNA and/or the translation efficiency of mRNA.
Nº publicación: EP4624516A1 01/10/2025
Solicitante:
KOREA INST SCI & TECH [KR]
Korea Institute of Science and Technology
Resumen de: EP4624516A1
Provided are a novel lipid derivative compound including oligo-γ-glutamic acid, a lipid nanoparticle composition including the same, and the like. According to the present disclosure, the compound may form lipid nanoparticles by replacing PEGylated lipid, thereby preventing side effects such as anaphylaxis and exhibiting excellent in vivo stability.
BOPI
Sede Electrónica
